Cutaneous T- Cell Lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast-2028
This report can be delivered to the clients within 24 Hours
DelveInsight’s ‘Cutaneous T- Cell Lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Cutaneous T- Cell Lymphoma (CTCL) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Cutaneous T- Cell Lymphoma (CTCL) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Cutaneous T- Cell Lymphoma (CTCL) - Disease Understanding and Treatment Algorithm
Cutaneous T-cell lymphoma (CTCL) is a group of lympho proliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. Collectively, CTCL is classified as a type of non-Hodgkin lymphoma (NHL). Cutaneous T-cell lymphomas (CTCL) are the most common types of skin lymphoma. More than 3 out of every 4 skin lymphomas diagnosed are CTCLs. They often appear as eczema-like skin rashes and can affect widespread parts of the body. There are different subtypes of CTCL. The most common type is mycosis fungoides. In some cases CTCL or Cutaneous T-Cell Lymphoma can affect more than just the skin and cause formation of tumor, exfoliation, and ulceration accompanied by infections and itching. In the advanced stages CTCL or Cutaneous T-Cell Lymphoma begins to extend to lymph nodes, internal organs and peripheral blood. CTCL or Cutaneous T-Cell Lymphoma is not a life threatening disease and mostly it can be treated but not cured.
The DelveInsight Cutaneous T- Cell Lymphoma (CTCL) market report gives a thorough understanding of the Cutaneous T- Cell Lymphoma (CTCL) by including details such as disease definition, types, staging, causes, pathophysiology, symptoms and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Cutaneous T- Cell Lymphoma (CTCL) in the United States, EU5 (Germany, Spain, France, Italy, the UK) & Japan.
Cutaneous T- Cell Lymphoma (CTCL) Epidemiology
The Cutaneous T- Cell Lymphoma (CTCL) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by incident population, sub-type specific incident population, gender-specific incidence population and stage specific incidence cases of Cutaneous T- Cell Lymphoma (CTCL).
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the incident population of Cutaneous T- Cell Lymphoma (CTCL) was estimated to be 8,617 [7MM] in 2018. United States accounts for the highest Cutaneous T- Cell Lymphoma (CTCL) cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries UK had the highest prevalent patient population of Cutaneous T- Cell Lymphoma (CTCL), followed by Germany.
Cutaneous T- Cell Lymphoma (CTCL) Drug Chapters
This segment of the Cutaneous T- Cell Lymphoma (CTCL) report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are currently seven approved therapies including Istodax, Potelegio and Uvadex, which are being used for the treatment of Cutaneous T- Cell Lymphoma (CTCL). However these drugs have shown to be effective in managing the Cutaneous T- Cell Lymphoma (CTCL) by reducing symptoms, risk of complications, and exacerbations among persons with CTCL. Though there are treatments available for Cutaneous T Cell Lymphoma (CTCL) but the available options are limited. There is no cure available for CTCL and the available treatments are for management of CTCL. The patients are treated with consecutive therapies until loss of response or without treatment ‘expectant therapy’ if no suitable therapy is available. Detailed chapters for all of these marketed drugs along with the other promising candidates like Adcetris and Zolinza have also been covered in the report.
Cutaneous T- Cell Lymphoma (CTCL) Market Outlook
The Cutaneous T- Cell Lymphoma (CTCL) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Cutaneous T- Cell Lymphoma (CTCL) was estimated to be USD 785.24 million in 2018. The United States accounts for the largest market size of Cutaneous T- Cell Lymphoma (CTCL), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
The dynamics of Cutaneous T- Cell Lymphoma (CTCL) market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Cutaneous T- Cell Lymphoma (CTCL). Upcoming therapies such as Soligenix’s SGX301, Janssen’s Quisinostat and many more, have the potential to create a significant positive shift in the Cutaneous T- Cell Lymphoma (CTCL) market size. The United States accounts for the largest market size of Cutaneous T- Cell Lymphoma (CTCL), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Cutaneous T- Cell Lymphoma (CTCL) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The market size of Cutaneous T- Cell Lymphoma (CTCL) includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
To counter current unmet needs of the market and to provide better treatment options for Cutaneous T- Cell Lymphoma (CTCL), several companies are working robustly on developing new therapies with novel mechanism of action.
Cutaneous T- Cell Lymphoma (CTCL) Report Insights
DelveInsight’s ‘Cutaneous T- Cell Lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Cutaneous T- Cell Lymphoma (CTCL) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Cutaneous T- Cell Lymphoma (CTCL) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Cutaneous T- Cell Lymphoma (CTCL) - Disease Understanding and Treatment Algorithm
Cutaneous T-cell lymphoma (CTCL) is a group of lympho proliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. Collectively, CTCL is classified as a type of non-Hodgkin lymphoma (NHL). Cutaneous T-cell lymphomas (CTCL) are the most common types of skin lymphoma. More than 3 out of every 4 skin lymphomas diagnosed are CTCLs. They often appear as eczema-like skin rashes and can affect widespread parts of the body. There are different subtypes of CTCL. The most common type is mycosis fungoides. In some cases CTCL or Cutaneous T-Cell Lymphoma can affect more than just the skin and cause formation of tumor, exfoliation, and ulceration accompanied by infections and itching. In the advanced stages CTCL or Cutaneous T-Cell Lymphoma begins to extend to lymph nodes, internal organs and peripheral blood. CTCL or Cutaneous T-Cell Lymphoma is not a life threatening disease and mostly it can be treated but not cured.
The DelveInsight Cutaneous T- Cell Lymphoma (CTCL) market report gives a thorough understanding of the Cutaneous T- Cell Lymphoma (CTCL) by including details such as disease definition, types, staging, causes, pathophysiology, symptoms and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Cutaneous T- Cell Lymphoma (CTCL) in the United States, EU5 (Germany, Spain, France, Italy, the UK) & Japan.
Cutaneous T- Cell Lymphoma (CTCL) Epidemiology
The Cutaneous T- Cell Lymphoma (CTCL) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by incident population, sub-type specific incident population, gender-specific incidence population and stage specific incidence cases of Cutaneous T- Cell Lymphoma (CTCL).
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the incident population of Cutaneous T- Cell Lymphoma (CTCL) was estimated to be 8,617 [7MM] in 2018. United States accounts for the highest Cutaneous T- Cell Lymphoma (CTCL) cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries UK had the highest prevalent patient population of Cutaneous T- Cell Lymphoma (CTCL), followed by Germany.
Cutaneous T- Cell Lymphoma (CTCL) Drug Chapters
This segment of the Cutaneous T- Cell Lymphoma (CTCL) report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are currently seven approved therapies including Istodax, Potelegio and Uvadex, which are being used for the treatment of Cutaneous T- Cell Lymphoma (CTCL). However these drugs have shown to be effective in managing the Cutaneous T- Cell Lymphoma (CTCL) by reducing symptoms, risk of complications, and exacerbations among persons with CTCL. Though there are treatments available for Cutaneous T Cell Lymphoma (CTCL) but the available options are limited. There is no cure available for CTCL and the available treatments are for management of CTCL. The patients are treated with consecutive therapies until loss of response or without treatment ‘expectant therapy’ if no suitable therapy is available. Detailed chapters for all of these marketed drugs along with the other promising candidates like Adcetris and Zolinza have also been covered in the report.
Cutaneous T- Cell Lymphoma (CTCL) Market Outlook
The Cutaneous T- Cell Lymphoma (CTCL) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Cutaneous T- Cell Lymphoma (CTCL) was estimated to be USD 785.24 million in 2018. The United States accounts for the largest market size of Cutaneous T- Cell Lymphoma (CTCL), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
The dynamics of Cutaneous T- Cell Lymphoma (CTCL) market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Cutaneous T- Cell Lymphoma (CTCL). Upcoming therapies such as Soligenix’s SGX301, Janssen’s Quisinostat and many more, have the potential to create a significant positive shift in the Cutaneous T- Cell Lymphoma (CTCL) market size. The United States accounts for the largest market size of Cutaneous T- Cell Lymphoma (CTCL), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Cutaneous T- Cell Lymphoma (CTCL) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The market size of Cutaneous T- Cell Lymphoma (CTCL) includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
To counter current unmet needs of the market and to provide better treatment options for Cutaneous T- Cell Lymphoma (CTCL), several companies are working robustly on developing new therapies with novel mechanism of action.
Cutaneous T- Cell Lymphoma (CTCL) Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Cutaneous T- Cell Lymphoma (CTCL) market.
- Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T- Cell Lymphoma (CTCL) market.
- To understand the future market competition in the Cutaneous T- Cell Lymphoma (CTCL) market.
1 KEY INSIGHTS
2 CUTANEOUS T- CELL LYMPHOMA (CTCL): MARKET OVERVIEW AT A GLANCE
2.1 Total Market Share (%) Distribution of Cutaneous T- Cell Lymphoma (CTCL) in 2016
2.2 Total Market Share (%) Distribution of Cutaneous T- Cell Lymphoma (CTCL) in 2027
3 DISEASE BACKGROUND AND OVERVIEW: CUTANEOUS T- CELL LYMPHOMA (CTCL)
3.1 Introduction
3.2 Types
3.3 Staging
3.4 Causes
3.5 Pathophysiology
3.6 Symptoms
3.7 Diagnosis
4 EPIDEMIOLOGY AND PATIENT POPULATION
4.1 Key Findings
4.2 Population and Forecast Parameters
5 INCIDENT POPULATION OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN 7MM
6 COUNTRY WISE-EPIDEMIOLOGY OF CUTANEOUS T- CELL LYMPHOMA (CTCL)
6.1 United States
6.1.1 Incident Population of CTCL in the United States
6.1.2 Sub Type Specific Incident Population of CTCL in the United States
6.1.3 Gender Specific Incidence of CTCL in the United States
6.1.4 Stage-Specific Incidence of CTCL (MF/SS) in the United States
6.2 EU5 Countries
6.3 Germany
6.3.1 Incident Population of CTCL in Germany
6.3.2 Sub Type Specific Incident Population of CTCL in Germany
6.3.3 Gender Specific Incidence of CTCL in Germany
6.3.4 Stage-Specific Incidence of CTCL (MF/SS) in Germany
6.4 France
6.4.1 Incident Population of CTCL in France
6.4.2 Sub Type Specific Incident Population of CTCL in France
6.4.3 Gender Specific Incidence of CTCL in France
6.4.4 Stage-Specific Incidence of CTCL (MF/SS) in France
6.5 Italy
6.5.1 Incident Population of CTCL in Italy
6.5.2 Sub Type Specific Incident Population of CTCL in Italy
6.5.3 Gender Specific Incidence of CTCL in Italy
6.5.4 Stage-Specific Incidence of CTCL (MF/SS) in Italy
6.6 Spain
6.6.1 Incident Population of CTCL in Spain
6.6.2 Sub Type Specific Incident Population of CTCL in Spain
6.6.3 Gender Specific Incidence of CTCL in Spain
6.6.4 Stage-Specific Incidence of CTCL (MF/SS) in Spain
6.7 The United Kingdom
6.7.1 Incident Population of CTCL in the United Kingdom
6.7.2 Sub Type Specific Incident Population of CTCL in the United Kingdom
6.7.3 Gender Specific Incidence of CTCL in the United Kingdom
6.7.4 Stage-Specific Incidence of CTCL (MF/SS) in the United Kingdom
6.8 Japan
6.8.1 Incident Population of CTCL in Japan
6.8.2 Sub Type Specific Incident Population of CTCL in Japan
6.8.3 Gender Specific Incidence of CTCL in Japan
6.8.4 Stage-Specific Incidence of CTCL (MF/SS) in Japan
7 TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
7.1 International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas
7.2 United States
7.2.1 NCCN Guidelines
7.3 Europe
7.3.1 ESMO Guidelines
7.3.2 Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines
7.3.3 EORTC recommendations for the treatment of mycosis fungoides/Seґzary syndrome
8 UNMET NEEDS
9 MARKETED DRUGS
9.1 Istodax (Romidepsin): Celgene Corporation
9.1.1 Drug Description
9.1.2 Mechanism of Action:
9.1.3 Regulatory Milestones
9.1.4 Advantages and Disadvantages
9.1.5 Safety and Efficacy
9.1.6 Advantages & Disadvantages
9.1.7 Product Profile
9.2 Potelegio (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.
9.2.1 Drug Description
9.2.2 Mechanism of Action
9.2.3 Regulatory Milestones
9.2.4 Advantages & Disadvantages
9.2.5 Safety and Efficacy
9.2.6 Product Profile
9.3 Valchlor/ Ledaga (Mechlorethamine): Actelion
9.3.1 Drug Description
9.3.2 Mechanism of Action
9.3.3 Regulatory Milestones
9.3.4 Advantages & Disadvantages
9.3.5 Safety and Efficacy
9.3.6 Product Profile
9.4 Uvadex (Methoxsalen): Mallinckrodt Pharmaceuticals
9.4.1 Drug Description
9.4.2 Mechanism of Action
9.4.3 Regulatory Milestones
9.4.4 Advantages & Disadvantages
9.4.5 Safety and Efficacy
9.4.6 Product Profile
9.5 Targretin (Bexarotene): Eisai Co., Ltd.
9.5.1 Drug Description
9.5.2 Mechanism of Action
9.5.3 Regulatory Milestones
9.5.4 Advantages & Disadvantages
9.5.5 Safety and Efficacy of Targretin
9.5.6 Product Profile
9.6 Zolinza (Vorinostat): Merck Sharp & Dohme Corp.
9.6.1 Drug Description
9.6.2 Mechanism of Action
9.6.3 Advantages & Disadvantages
9.6.4 Safety and Efficacy of Zolinza
9.6.5 Product Profile
9.7 Adcetris (Brentuximab Vedotin): Seattle Genetics
9.7.1 Drug Description
9.7.2 Mechanism of Action
9.7.3 Regulatory Milestones
9.7.4 Advantages & Disadvantages
9.7.5 Safety and Efficacy of Adcetris
9.7.6 Product Profile
10 EMERGING THERAPIES
10.1 Phase-III Drugs Analysis – Monoclonal Antibodies and Photodynamic Therapy
10.2 Phase-II Drugs Analysis - Histone Deacetylase (HDAC) Inhibitors
10.3 SGX301: Soligenix
10.3.1 Product Description
10.3.2 Regulatory Milestones
10.3.3 Clinical Development
10.3.4 Product Profile
10.4 Quisinostat: Janssen
10.4.1 Product Description
10.4.2 Regulatory Milestones
10.4.3 Clinical Development
10.4.4 Safety and Efficacy
10.4.5 Product Profile
10.5 Resminostat: 4SC AG
10.5.1 Product Description
10.5.2 Regulatory Milestones
10.5.3 Clinical Development
10.5.4 Product Profile
10.6 Remetinostat: Medivir AB
10.6.1 Product Description
10.6.2 Regulatory Milestones
10.6.3 Clinical Development
10.6.4 Safety and Efficacy
10.6.5 Product Profile
11 CUTANEOUS T- CELL LYMPHOMA (CTCL): 7 MAJOR MARKET ANALYSIS
11.1 Key Findings
11.2 Total Market Size of Cutaneous T- Cell Lymphoma (CTCL) in 7MM
11.3 Early Stage Market Size of Cutaneous T- Cell Lymphoma (CTCL) in 7 MM
11.4 Late Stage Market Size of Cutaneous T- Cell Lymphoma (CTCL) in 7 MM
12 THE UNITED STATES MARKET OUTLOOK
12.1 United States Market Size
12.1.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in US
12.1.2 Early Stage Market Size of CTCL by First Line of Therapies in US
12.1.3 Early Stage Market Size of CTCL by Second Line of Therapies in US
12.1.4 Late Stage Market Size of CTCL by First Line of Therapies in US
12.1.5 Late Stage Market Size of CTCL by Second Line of Therapies in US
13 EU-5 COUNTRIES: MARKET OUTLOOK
13.1 Germany
13.1.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in Germany
13.1.2 Early Stage Market Size of CTCL by First Line of Therapies in Germany
13.1.3 Early Stage Market Size of CTCL by Second Line of Therapies in Germany
13.1.4 Late Stage Market Size of CTCL by First Line of Therapies in Germany
13.1.5 Late Stage Market Size of CTCL by Second Line of Therapies in Germany
13.2 France
13.2.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in France
13.2.2 Early Stage Market Size of CTCL by First Line of Therapies in France
13.2.3 Early Stage Market Size of CTCL by Second Line of Therapies in France
13.2.4 Late Stage Market Size of CTCL by First Line of Therapies in France
13.2.5 Late Stage Market Size of CTCL by Second Line of Therapies in France
13.2.6
13.3 Italy
13.3.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in Italy
13.3.2 Early Stage Market Size of CTCL by First Line of Therapies in Italy
13.3.3 Early Stage Market Size of CTCL by Second Line of Therapies in Italy
13.3.4 Late Stage Market Size of CTCL by First Line of Therapies in Italy
13.3.5 Late Stage Market Size of CTCL by Second Line of Therapies in Italy
13.4 Spain
13.4.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in Spain
13.4.2 Early Stage Market Size of CTCL by First Line of Therapies in Spain
13.4.3 Early Stage Market Size of CTCL by Second Line of Therapies in Spain
13.4.4 Late Stage Market Size of CTCL by First Line of Therapies in Spain
13.4.5 Late Stage Market Size of CTCL by Second Line of Therapies in Spain
13.5 United Kingdom
13.5.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in UK
13.5.2 Early Stage Market Size of CTCL by First Line of Therapies in UK
13.5.3 Early Stage Market Size of CTCL by Second Line of Therapies in UK
13.5.4 Late Stage Market Size of CTCL by First Line of Therapies in UK
13.5.5 Late Stage Market Size of CTCL by Second Line of Therapies in UK
13.6 Japan: Market Outlook
13.6.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in Japan
13.6.2 Early Stage Market Size of CTCL by First Line of Therapies in Japan
13.6.3 Early Stage Market Size of CTCL by Second Line of Therapies in Japan
13.6.4 Late Stage Market Size of CTCL by First Line of Therapies in Japan
13.6.5 Late Stage Market Size of CTCL by Second Line of Therapies in Japan
14 MARKET DRIVERS
15 MARKET BARRIERS
16 APPENDIX
17 REPORT METHODOLOGY
17.1 Sources Used
18 DELVEINSIGHT CAPABILITIES
19 DISCLAIMER
20 ABOUT DELVEINSIGHT
2 CUTANEOUS T- CELL LYMPHOMA (CTCL): MARKET OVERVIEW AT A GLANCE
2.1 Total Market Share (%) Distribution of Cutaneous T- Cell Lymphoma (CTCL) in 2016
2.2 Total Market Share (%) Distribution of Cutaneous T- Cell Lymphoma (CTCL) in 2027
3 DISEASE BACKGROUND AND OVERVIEW: CUTANEOUS T- CELL LYMPHOMA (CTCL)
3.1 Introduction
3.2 Types
3.3 Staging
3.4 Causes
3.5 Pathophysiology
3.6 Symptoms
3.7 Diagnosis
4 EPIDEMIOLOGY AND PATIENT POPULATION
4.1 Key Findings
4.2 Population and Forecast Parameters
5 INCIDENT POPULATION OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN 7MM
6 COUNTRY WISE-EPIDEMIOLOGY OF CUTANEOUS T- CELL LYMPHOMA (CTCL)
6.1 United States
6.1.1 Incident Population of CTCL in the United States
6.1.2 Sub Type Specific Incident Population of CTCL in the United States
6.1.3 Gender Specific Incidence of CTCL in the United States
6.1.4 Stage-Specific Incidence of CTCL (MF/SS) in the United States
6.2 EU5 Countries
6.3 Germany
6.3.1 Incident Population of CTCL in Germany
6.3.2 Sub Type Specific Incident Population of CTCL in Germany
6.3.3 Gender Specific Incidence of CTCL in Germany
6.3.4 Stage-Specific Incidence of CTCL (MF/SS) in Germany
6.4 France
6.4.1 Incident Population of CTCL in France
6.4.2 Sub Type Specific Incident Population of CTCL in France
6.4.3 Gender Specific Incidence of CTCL in France
6.4.4 Stage-Specific Incidence of CTCL (MF/SS) in France
6.5 Italy
6.5.1 Incident Population of CTCL in Italy
6.5.2 Sub Type Specific Incident Population of CTCL in Italy
6.5.3 Gender Specific Incidence of CTCL in Italy
6.5.4 Stage-Specific Incidence of CTCL (MF/SS) in Italy
6.6 Spain
6.6.1 Incident Population of CTCL in Spain
6.6.2 Sub Type Specific Incident Population of CTCL in Spain
6.6.3 Gender Specific Incidence of CTCL in Spain
6.6.4 Stage-Specific Incidence of CTCL (MF/SS) in Spain
6.7 The United Kingdom
6.7.1 Incident Population of CTCL in the United Kingdom
6.7.2 Sub Type Specific Incident Population of CTCL in the United Kingdom
6.7.3 Gender Specific Incidence of CTCL in the United Kingdom
6.7.4 Stage-Specific Incidence of CTCL (MF/SS) in the United Kingdom
6.8 Japan
6.8.1 Incident Population of CTCL in Japan
6.8.2 Sub Type Specific Incident Population of CTCL in Japan
6.8.3 Gender Specific Incidence of CTCL in Japan
6.8.4 Stage-Specific Incidence of CTCL (MF/SS) in Japan
7 TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
7.1 International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas
7.2 United States
7.2.1 NCCN Guidelines
7.3 Europe
7.3.1 ESMO Guidelines
7.3.2 Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines
7.3.3 EORTC recommendations for the treatment of mycosis fungoides/Seґzary syndrome
8 UNMET NEEDS
9 MARKETED DRUGS
9.1 Istodax (Romidepsin): Celgene Corporation
9.1.1 Drug Description
9.1.2 Mechanism of Action:
9.1.3 Regulatory Milestones
9.1.4 Advantages and Disadvantages
9.1.5 Safety and Efficacy
9.1.6 Advantages & Disadvantages
9.1.7 Product Profile
9.2 Potelegio (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.
9.2.1 Drug Description
9.2.2 Mechanism of Action
9.2.3 Regulatory Milestones
9.2.4 Advantages & Disadvantages
9.2.5 Safety and Efficacy
9.2.6 Product Profile
9.3 Valchlor/ Ledaga (Mechlorethamine): Actelion
9.3.1 Drug Description
9.3.2 Mechanism of Action
9.3.3 Regulatory Milestones
9.3.4 Advantages & Disadvantages
9.3.5 Safety and Efficacy
9.3.6 Product Profile
9.4 Uvadex (Methoxsalen): Mallinckrodt Pharmaceuticals
9.4.1 Drug Description
9.4.2 Mechanism of Action
9.4.3 Regulatory Milestones
9.4.4 Advantages & Disadvantages
9.4.5 Safety and Efficacy
9.4.6 Product Profile
9.5 Targretin (Bexarotene): Eisai Co., Ltd.
9.5.1 Drug Description
9.5.2 Mechanism of Action
9.5.3 Regulatory Milestones
9.5.4 Advantages & Disadvantages
9.5.5 Safety and Efficacy of Targretin
9.5.6 Product Profile
9.6 Zolinza (Vorinostat): Merck Sharp & Dohme Corp.
9.6.1 Drug Description
9.6.2 Mechanism of Action
9.6.3 Advantages & Disadvantages
9.6.4 Safety and Efficacy of Zolinza
9.6.5 Product Profile
9.7 Adcetris (Brentuximab Vedotin): Seattle Genetics
9.7.1 Drug Description
9.7.2 Mechanism of Action
9.7.3 Regulatory Milestones
9.7.4 Advantages & Disadvantages
9.7.5 Safety and Efficacy of Adcetris
9.7.6 Product Profile
10 EMERGING THERAPIES
10.1 Phase-III Drugs Analysis – Monoclonal Antibodies and Photodynamic Therapy
10.2 Phase-II Drugs Analysis - Histone Deacetylase (HDAC) Inhibitors
10.3 SGX301: Soligenix
10.3.1 Product Description
10.3.2 Regulatory Milestones
10.3.3 Clinical Development
10.3.4 Product Profile
10.4 Quisinostat: Janssen
10.4.1 Product Description
10.4.2 Regulatory Milestones
10.4.3 Clinical Development
10.4.4 Safety and Efficacy
10.4.5 Product Profile
10.5 Resminostat: 4SC AG
10.5.1 Product Description
10.5.2 Regulatory Milestones
10.5.3 Clinical Development
10.5.4 Product Profile
10.6 Remetinostat: Medivir AB
10.6.1 Product Description
10.6.2 Regulatory Milestones
10.6.3 Clinical Development
10.6.4 Safety and Efficacy
10.6.5 Product Profile
11 CUTANEOUS T- CELL LYMPHOMA (CTCL): 7 MAJOR MARKET ANALYSIS
11.1 Key Findings
11.2 Total Market Size of Cutaneous T- Cell Lymphoma (CTCL) in 7MM
11.3 Early Stage Market Size of Cutaneous T- Cell Lymphoma (CTCL) in 7 MM
11.4 Late Stage Market Size of Cutaneous T- Cell Lymphoma (CTCL) in 7 MM
12 THE UNITED STATES MARKET OUTLOOK
12.1 United States Market Size
12.1.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in US
12.1.2 Early Stage Market Size of CTCL by First Line of Therapies in US
12.1.3 Early Stage Market Size of CTCL by Second Line of Therapies in US
12.1.4 Late Stage Market Size of CTCL by First Line of Therapies in US
12.1.5 Late Stage Market Size of CTCL by Second Line of Therapies in US
13 EU-5 COUNTRIES: MARKET OUTLOOK
13.1 Germany
13.1.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in Germany
13.1.2 Early Stage Market Size of CTCL by First Line of Therapies in Germany
13.1.3 Early Stage Market Size of CTCL by Second Line of Therapies in Germany
13.1.4 Late Stage Market Size of CTCL by First Line of Therapies in Germany
13.1.5 Late Stage Market Size of CTCL by Second Line of Therapies in Germany
13.2 France
13.2.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in France
13.2.2 Early Stage Market Size of CTCL by First Line of Therapies in France
13.2.3 Early Stage Market Size of CTCL by Second Line of Therapies in France
13.2.4 Late Stage Market Size of CTCL by First Line of Therapies in France
13.2.5 Late Stage Market Size of CTCL by Second Line of Therapies in France
13.2.6
13.3 Italy
13.3.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in Italy
13.3.2 Early Stage Market Size of CTCL by First Line of Therapies in Italy
13.3.3 Early Stage Market Size of CTCL by Second Line of Therapies in Italy
13.3.4 Late Stage Market Size of CTCL by First Line of Therapies in Italy
13.3.5 Late Stage Market Size of CTCL by Second Line of Therapies in Italy
13.4 Spain
13.4.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in Spain
13.4.2 Early Stage Market Size of CTCL by First Line of Therapies in Spain
13.4.3 Early Stage Market Size of CTCL by Second Line of Therapies in Spain
13.4.4 Late Stage Market Size of CTCL by First Line of Therapies in Spain
13.4.5 Late Stage Market Size of CTCL by Second Line of Therapies in Spain
13.5 United Kingdom
13.5.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in UK
13.5.2 Early Stage Market Size of CTCL by First Line of Therapies in UK
13.5.3 Early Stage Market Size of CTCL by Second Line of Therapies in UK
13.5.4 Late Stage Market Size of CTCL by First Line of Therapies in UK
13.5.5 Late Stage Market Size of CTCL by Second Line of Therapies in UK
13.6 Japan: Market Outlook
13.6.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in Japan
13.6.2 Early Stage Market Size of CTCL by First Line of Therapies in Japan
13.6.3 Early Stage Market Size of CTCL by Second Line of Therapies in Japan
13.6.4 Late Stage Market Size of CTCL by First Line of Therapies in Japan
13.6.5 Late Stage Market Size of CTCL by Second Line of Therapies in Japan
14 MARKET DRIVERS
15 MARKET BARRIERS
16 APPENDIX
17 REPORT METHODOLOGY
17.1 Sources Used
18 DELVEINSIGHT CAPABILITIES
19 DISCLAIMER
20 ABOUT DELVEINSIGHT
LIST OF TABLES
TABLE 1: TOTAL INCIDENT POPULATION OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN THE 7MM (2016-2027)
TABLE 2: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
TABLE 3: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
TABLE 4: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
TABLE 5: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
TABLE 6: LATE STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
TABLE 7: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
TABLE 8: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
TABLE 9: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
TABLE 10: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
TABLE 11: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
TABLE 12: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
TABLE 13: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
TABLE 14: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
TABLE 15: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
TABLE 16: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
TABLE 17: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
TABLE 18: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
TABLE 19: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
TABLE 20: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
TABLE 21: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
TABLE 22: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
TABLE 23: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
TABLE 24: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
TABLE 25: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
TABLE 26: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
TABLE 27: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
TABLE 28: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
TABLE 29: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
TABLE 30: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
TABLE 31 : RECOMMENDATIONS FOR TREATMENT OF CTCL BY RADIATION THERAPY
TABLE 32: BAD GUIDELINES FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME
TABLE 33 : RECOMMENDATIONS FOR TREATMENT OF MF STAGES IA, IB, AND IIA
TABLE 34: 7 MAJOR MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 35: 7 MAJOR MARKET SIZE OF EARLY STAGE CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 36: 7 MAJOR MARKET SIZE OF LATE STAGE CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 37: UNITED STATES MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 38: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
TABLE 39: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
TABLE 40: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
TABLE 41: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
TABLE 42: GERMANY MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 43: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
TABLE 44: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
TABLE 45: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
TABLE 46: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
TABLE 47: FRENCH MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 48: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
TABLE 49: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
TABLE 50: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
TABLE 51: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
TABLE 52: ITALIAN MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 53: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
TABLE 54: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
TABLE 55: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
TABLE 56: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
TABLE 57: SPANISH MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 58: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
TABLE 59: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
TABLE 60: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
TABLE 61: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
TABLE 62: UK MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 63: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
TABLE 64: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
TABLE 65: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
TABLE 66: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
TABLE 67: JAPANESE MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 68: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
TABLE 69: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
TABLE 70: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
TABLE 71: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
TABLE 1: TOTAL INCIDENT POPULATION OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN THE 7MM (2016-2027)
TABLE 2: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
TABLE 3: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
TABLE 4: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
TABLE 5: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
TABLE 6: LATE STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
TABLE 7: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
TABLE 8: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
TABLE 9: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
TABLE 10: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
TABLE 11: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
TABLE 12: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
TABLE 13: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
TABLE 14: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
TABLE 15: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
TABLE 16: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
TABLE 17: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
TABLE 18: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
TABLE 19: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
TABLE 20: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
TABLE 21: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
TABLE 22: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
TABLE 23: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
TABLE 24: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
TABLE 25: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
TABLE 26: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
TABLE 27: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
TABLE 28: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
TABLE 29: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
TABLE 30: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
TABLE 31 : RECOMMENDATIONS FOR TREATMENT OF CTCL BY RADIATION THERAPY
TABLE 32: BAD GUIDELINES FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME
TABLE 33 : RECOMMENDATIONS FOR TREATMENT OF MF STAGES IA, IB, AND IIA
TABLE 34: 7 MAJOR MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 35: 7 MAJOR MARKET SIZE OF EARLY STAGE CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 36: 7 MAJOR MARKET SIZE OF LATE STAGE CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 37: UNITED STATES MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 38: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
TABLE 39: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
TABLE 40: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
TABLE 41: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
TABLE 42: GERMANY MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 43: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
TABLE 44: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
TABLE 45: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
TABLE 46: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
TABLE 47: FRENCH MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 48: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
TABLE 49: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
TABLE 50: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
TABLE 51: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
TABLE 52: ITALIAN MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 53: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
TABLE 54: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
TABLE 55: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
TABLE 56: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
TABLE 57: SPANISH MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 58: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
TABLE 59: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
TABLE 60: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
TABLE 61: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
TABLE 62: UK MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 63: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
TABLE 64: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
TABLE 65: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
TABLE 66: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
TABLE 67: JAPANESE MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
TABLE 68: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
TABLE 69: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
TABLE 70: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
TABLE 71: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
LIST OF FIGURES
FIGURE 1: STAGING OF CUTANEOUS T-CELL LYMPHOMA: TNMB CLASSIFICATION
FIGURE 2: TOTAL INCIDENT PATIENT POPULATION OF CTCL IN THE 7MM (2016-2027)
FIGURE 3: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
FIGURE 4: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
FIGURE 5: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
FIGURE 6: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
FIGURE 7: LATE STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
FIGURE 8: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
FIGURE 9: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
FIGURE 10: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
FIGURE 11: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
FIGURE 12: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
FIGURE 13: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
FIGURE 14: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
FIGURE 15: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
FIGURE 16: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
FIGURE 17: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
FIGURE 18: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
FIGURE 19: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
FIGURE 20: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
FIGURE 21: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
FIGURE 22: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
FIGURE 23: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
FIGURE 24: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
FIGURE 25: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
FIGURE 26: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
FIGURE 27: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
FIGURE 28: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
FIGURE 29: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
FIGURE 30: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
FIGURE 31: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
FIGURE 32: TREATMENT ALGORITHM OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 33: TREATMENT ALGORITHM OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 34:TREATMENT FOR STAGE IA OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 35:TREATMENT FOR STAGE IB-IIA OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 36:TREATMENT FOR STAGE IIB OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 37:TREATMENT FOR STAGE III OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 38:TREATMENT FOR STAGE IV OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 39:TREATMENT FOR PRIMARY CUTANEOUS CD30+ T-CELL LYMPHOPROLIFERATIVE DISORDERS
FIGURE 40:TREATMENT FOR LYMPHOMATOID PAPULOSIS
FIGURE 41: UNMET NEEDS OF CUTANEOUS T- CELL LYMPHOMA (CTCL)
FIGURE 42: 7 MAJOR MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
FIGURE 43: 7MM SIZE OF EARLY STAGE CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
FIGURE 44: 7MM SIZE OF LATE STAGE CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
FIGURE 45: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN THE UNITED STATES, USD MILLIONS (2016-2027)
FIGURE 46: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
FIGURE 47: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
FIGURE 48: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
FIGURE 49: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
FIGURE 50: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN GERMANY, USD MILLIONS (2016-2027)
FIGURE 51: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
FIGURE 52: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
FIGURE 53: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
FIGURE 54: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
FIGURE 55: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN FRANCE, USD MILLIONS (2016-2027)
FIGURE 56: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
FIGURE 57: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
FIGURE 58: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
FIGURE 59: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
FIGURE 60: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN ITALY, USD MILLIONS (2016-2027)
FIGURE 61: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
FIGURE 62: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
FIGURE 63: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
FIGURE 64: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
FIGURE 65: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN SPAIN, USD MILLIONS (2016-2027)
FIGURE 66: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
FIGURE 67: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
FIGURE 68: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
FIGURE 69: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
FIGURE 70: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN UK, USD MILLIONS (2016-2027)
FIGURE 71: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
FIGURE 72: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
FIGURE 73: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
FIGURE 74: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
FIGURE 75: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN JAPAN, USD MILLIONS (2016-2027)
FIGURE 76: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
FIGURE 77: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
FIGURE 78: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
FIGURE 79: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
FIGURE 80: MARKET DRIVERS
FIGURE 81: MARKET BARRIERS
FIGURE 1: STAGING OF CUTANEOUS T-CELL LYMPHOMA: TNMB CLASSIFICATION
FIGURE 2: TOTAL INCIDENT PATIENT POPULATION OF CTCL IN THE 7MM (2016-2027)
FIGURE 3: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
FIGURE 4: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
FIGURE 5: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
FIGURE 6: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
FIGURE 7: LATE STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)
FIGURE 8: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
FIGURE 9: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
FIGURE 10: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
FIGURE 11: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)
FIGURE 12: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
FIGURE 13: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
FIGURE 14: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
FIGURE 15: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)
FIGURE 16: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
FIGURE 17: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
FIGURE 18: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
FIGURE 19: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)
FIGURE 20: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
FIGURE 21: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
FIGURE 22: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
FIGURE 23: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)
FIGURE 24: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
FIGURE 25: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
FIGURE 26: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
FIGURE 27: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)
FIGURE 28: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
FIGURE 29: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
FIGURE 30: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
FIGURE 31: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)
FIGURE 32: TREATMENT ALGORITHM OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 33: TREATMENT ALGORITHM OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 34:TREATMENT FOR STAGE IA OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 35:TREATMENT FOR STAGE IB-IIA OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 36:TREATMENT FOR STAGE IIB OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 37:TREATMENT FOR STAGE III OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 38:TREATMENT FOR STAGE IV OF CUTANEOUS T- CELL LYMPHOMA
FIGURE 39:TREATMENT FOR PRIMARY CUTANEOUS CD30+ T-CELL LYMPHOPROLIFERATIVE DISORDERS
FIGURE 40:TREATMENT FOR LYMPHOMATOID PAPULOSIS
FIGURE 41: UNMET NEEDS OF CUTANEOUS T- CELL LYMPHOMA (CTCL)
FIGURE 42: 7 MAJOR MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
FIGURE 43: 7MM SIZE OF EARLY STAGE CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
FIGURE 44: 7MM SIZE OF LATE STAGE CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)
FIGURE 45: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN THE UNITED STATES, USD MILLIONS (2016-2027)
FIGURE 46: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
FIGURE 47: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
FIGURE 48: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
FIGURE 49: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)
FIGURE 50: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN GERMANY, USD MILLIONS (2016-2027)
FIGURE 51: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
FIGURE 52: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
FIGURE 53: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
FIGURE 54: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)
FIGURE 55: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN FRANCE, USD MILLIONS (2016-2027)
FIGURE 56: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
FIGURE 57: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
FIGURE 58: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
FIGURE 59: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)
FIGURE 60: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN ITALY, USD MILLIONS (2016-2027)
FIGURE 61: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
FIGURE 62: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
FIGURE 63: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
FIGURE 64: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)
FIGURE 65: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN SPAIN, USD MILLIONS (2016-2027)
FIGURE 66: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
FIGURE 67: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
FIGURE 68: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
FIGURE 69: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)
FIGURE 70: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN UK, USD MILLIONS (2016-2027)
FIGURE 71: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
FIGURE 72: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
FIGURE 73: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
FIGURE 74: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)
FIGURE 75: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN JAPAN, USD MILLIONS (2016-2027)
FIGURE 76: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
FIGURE 77: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
FIGURE 78: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
FIGURE 79: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)
FIGURE 80: MARKET DRIVERS
FIGURE 81: MARKET BARRIERS
